European Primary Care Cardiovascular Society

Effective lowering of CV events by non-steroidal MRA in patients with diabetes and CKD

5' education - Oct. 5, 2021 - Prof. Bertram Pitt, MD

A pooled analysis of two large HF trials with SGLT2i shows exciting findings

3' education - Oct. 5, 2021 - Milton Packer, MD

Benefit of SGLT2i in HFpEF by reduction of clinically meaningful CV events

3' education - Sep. 15, 2021 - Prof. Stefan Anker, MD, PhD

Reduction of stroke, CV events and death when switching to a salt substitute

5' education - Sep. 12, 2021 - Prof. Bruce Neal, MD, PhD

The 2021 ESC HF guidelines: What is new regarding patients with EF>40%?

3' education - Sep. 10, 2021 - Prof. Carolyn Lam, MD, PhD

After stopping therapy, continued benefit of statin treatment

5' education - July 12, 2021 - Jackie Bosch, PhD

IL-6 inhibition in CKD for CV risk reduction

5' education - June 1, 2021 - Prof. Paul Ridker, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

Statin-intolerant patients and lipid-lowering therapies

15' education - June 1, 2021 - Prof. Maciej Banach, MD, PhD and prof. Ulrich Laufs, MD, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

Current barriers and challenges in achieving LDL-c goals

15' education - June 1, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME

Controversy on omega-3FAs trials

5' education - May 27, 2021 - Prof. Eileen Handberg, PhD

Proven safety with ARNI in MI patients, but no definite difference for primary endpoint

5' education - May 27, 2021 - Prof. Marc Pfeffer, MD, PhD

Clinical outcomes not different with 81 mg vs. 325 mg aspirin in established CVD

5' education - May 26, 2021 - William Schuyler Jones, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

How are we doing: The gap between guideline LDL-c goals and current practice

15' education - May 11, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

Benefit of LDL-c lowering: a proven case

15' education - May 4, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD

Comparison of low dose vs. high dose DOAC in patients with AF

3' education - Apr. 21, 2021 - Prof. Jan Steffel, MD

CV and renal benefit predicted by reduction in albuminuria in T2DM

10' education - Apr. 15, 2021 - Frederik Persson, MD

Weight loss induction by GLP-1RA in adults with overweight or obesity

10' education - Mar. 25, 2021 - Prof. Robert Kushner, MD

High incidence of thrombotic complications in first and second COVID-19 wave

5' education - Mar. 5, 2021 - Fleur Kaptein, MD

The future of CV medicine: anti-inflammation

10' education - Mar. 5, 2021 - Prof. Paul Ridker, MD

Treat also older adults to lower LDL-c

5' education - Jan. 19, 2021 - Prof. Børge Nordestgaard, MD

Remote program for improvement of lipid and hypertension management

News - Nov. 22, 2021

AHA 2021 This remote hypertension and LDL-c management program enrolled over 10,000 patients at high CV risk. The program effectively improved hypertension and LDL-c control across a diverse health care network.

SGLT2i reduces composite of CV death or HF hospitalization in patients with HF and LVEF ≥50%

News - Nov. 17, 2021

AHA 2021 This analysis of the EMPEROR-Preserved trail showed that empagliflozin reduced the primary endpoint of time to first event of CV death or HF hospitalization by 17%, compared to placebo, in HF patients with LVEF ≥50%.

No significant effect of aspirin on dementia outcomes in patients with T2DM

News - Nov. 16, 2021

AHA 2021 Using data of the ASCEND trial, this study showed that there was no significant effect of aspirin on dementia outcomes compared to placebo in patients with T2DM.

Testing individual triggers for AF

News - Nov. 15, 2021

AHA 2021 In the I-STOP AF trial, n-of-1 trials with individual triggers did not result in a change in AF-related quality of life compared to monitoring only.

SGLT2 inhibitor improves symptoms in heart failure

News - Nov. 15, 2021

AHA 2021 The CHIEF-HF study showed that canagliflozin improved symptoms in HF as measured by KCCQ-TSS. The benefits with canagliflozin were observed as early as 2 weeks and sustained until the end of treatment at 3 months.

Highly-purified icosapent ethyl does not reduce clinical outcomes in non-hospitalized COVID-19 patients

News - Nov. 15, 2021

AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.

Screening for AF using a novel software algorithm with input of data of Fitbit wearables

News - Nov. 14, 2021
A novel software algorithm with input of irregular heart rhythm detection by Fitbit wearables had a positive predictive value of 98% for undiagnosed atrial fibrillation (AF).

AHA 2021 A novel software algorithm with input of irregular heart rhythm detection by Fitbit wearables had a positive predictive value of 98% for undiagnosed atrial fibrillation (AF).

No difference in cognitive outcomes in AF patients treated with DOAC vs. warfarin

News - Nov. 14, 2021

AHA 2021 The majority of cognitive outcome tests was not different between AF patients treated with dabigatran or warfarin after two years in the GIRAF trial.

Coffee consumption linked to more premature ventricular contractions, more physical activity and less sleep

News - Nov. 14, 2021

AHA 2021 This randomized trial assessed the acute physiologic consequences of coffee consumption and found that drinking coffee did not increase atrial arrhythmias but did result in more PVCs, less sleep and more physical activity.

BP control in rural China improved by village doctor-led intervention for hypertension treatment

News - Nov. 13, 2021

AHA 2021 In a cluster trial of villages, BP control was significantly improved by a village doctor-led intervention for hypertension treatment compared to usual care among hypertensive residents in rural China.

Lowest risk of developing CVD when going to sleep between 10 and 11 p.m.

Literature - Nov. 9, 2021 - Nikbakhtian S et al. - EHJ - Digital Health, 2021
This study assessed the association between objectively measured sleep onset and risk for developing CVD in a large cohort and found a U-shaped relationship between sleep onset time and CVD incidence.

This study assessed the association between objectively measured sleep onset and risk for developing CVD in a large cohort and found a U-shaped relationship between sleep onset time and CVD incidence.

SGLT2i reduces albuminuria in CKD patients with and without T2DM

Literature - Nov. 8, 2021 - Jongs N, et al. - Lancet Diabetes Endocrinol 2021

The SGLT2 inhibitor dapagliflozin reduced albuminuria compared to placebo in CKD patients with and without T2DM in the DAPA-CKD trial, with a more pronounced effect in patients with T2DM.

Agenda